Synaptic Dynamics, Inc., a University of Connecticut startup company, is screening a compound to stimulate the brain to use its own defenses to fight off Alzheimer’s disease, a neurodegenerative condition that has remained for the most part untreatable. But even with its slick ideas, the company has staggered in its efforts to raise capital.
Now there may be a white knight on the horizon — a new angel investment fund at UConn aimed at just such companies struggling to emerge into the marketplace.
Synaptic has had a tougher time in the business world than in the science realm. It lost its COO, saw a potential partnership dissolve, and has yet to attain venture capital. None of that is unusual for companies with technology or patent-ready ideas as they move from the sheltered university system and into the marketplace, say technology leaders at the school.
To read the full, original article click on this link: Bridging the ‘valley of death’ | Hartford Business
